Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis

Abstract

Mitochondrion is one of the master players in both apoptosis and necrosis. We studied the role of mitochondrial function in TRAIL-induced apoptosis. TRAIL killed SK-Hep1 cells with characteristic features of apoptosis such as DNA fragmentation, sub-G1 ploidy peak and cytochrome c translocation. In contrast, mitochondrial DNA-deficient SK-Hep1 ρ0 cells were resistant to TRAIL. Dissipation of mitochondrial potential or cytochrome c translocation did not occur in ρ0 cells after TRAIL treatment. TRAIL induced translocation of Bax subsequent to the cleavage of Bid in parental cells. However, Bax translocation was absent in ρ0 cells, accounting for the failure of cytochrome c release in ρ0 cells. Forced expression of Bax induced caspase-3 activity in ρ0 cells. Incubation of ρ0 cells with ADP+Pi to increase intracellular ATP restored sensitivity to TRAIL. Despite different sensitivity to TRAIL, parental cells and ρ0 cells did not show significant difference in susceptibility to agonistic anti-Fas antibody, TNF-α or staurosporine. Our results indicate that TRAIL-induced apoptosis is dependent on intact mitochondrial function and susceptibility of mitochondrial DNA-deficient cells to apoptosis depends on the type of apoptotic stimuli. Tumor cells with mitochondrial mutations or dysfunction might have the ability to evade tumor surveillance imposed by TRAIL in vivo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 5
Figure 2
Figure 3
Figure 4
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12

Similar content being viewed by others

References

  • Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD . 1994 Garland Pub. Inc. New York 3: 568–573

  • Bossy-Wentzel E, Newmeyer DD, Green DR . 1998 EMBO J. 17: 37–49

  • Buchet K, Gedinot C . 1998 J. Biol. Chem. 273: 22983–22989

  • Cha S-S, Kim M-S, Choi YH, Sung B-J, Shin NK, Shin H-C, Sung YC, Oh B-H . 1999 Immunity 11: 253–261

  • Cha S-S, Sung B-J, Kim Y-A, Song Y-L, Kim H-J, Kim S, Lee M-S, Oh B-H . 2000 J. Biol. Chem. 275: 31171–31177

  • Chaudhary PT, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L . 1997 Immunity 7: 821–830

  • Drgon T, Sabova L, Nelson N, Kolarov J . 1991 FEBS Letts 289: 159–162

  • Fanger NA, Maliszewski CR, Schooley K, Griffiths TS . 1999 J. Exp. Med. 190: 1155–1164

  • Fliss MS, Usadel H, Cabellero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransku D . 2000 Science 287: 2017–2019

  • Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ . 1998 J. Immunol. 161: 2833–2840

  • Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA . 1999 J. Exp. Med. 189: 1343–1354

  • Gross A, Jockel J, Wei MC, Korsmeyer SJ . 1998 EMBO J. 17: 3878–3885

  • Higuchi M, Aggarwal BB, Yeh ETH . 1997 J. Clin. Invest. 99: 1751–1758

  • Higuchi Y, Herrera P, Muniesa P, Huarte P, Belin D, Ohashi P, Aichele P, Orci L, Vassalli J-D, Vassalli P . 1992 J. Exp. Med. 176: 1719–1731

  • Hsu Y-T, Wolter KG, Youle RJ . 1997 Proc. Natl. Acad. Sci. USA 94: 3668–3672

  • Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC . 1993 Nature 361: 365–369

  • Jeremias I, Herr I, Boehler T, Debatin K . 1998 Eur. J. Immunol. 28: 143–152

  • Jia L, Patwari Y, Srinivasula SM, Newland AC, Fernandes-Alnemri T, Alnemri ES, Kelsey SM . 2001 Oncogene 20: 4817–4826

  • Jia L, Kelsey SM, Grahn MF, Jiang X-R, Newland AC . 1996 Blood 87: 2401–2410

  • Jiang SJ, Cai J, Wallace DC, Jones DP . 1999 J. Biol. Chem. 274: 29905–29911

  • Jones BE, Lo CR, Liu H, Srinivastan A, Streetz K, Valentino KL, Czaja M . 2000 J. Biol. Chem. 275: 705–712

  • Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, Yagita H . 1999a J. Immunol. 162: 2639–2647

  • Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H, Okumura H, Nakanishi K, Okumura K, Yagita H . 1999b J. Immunol. 163: 1906–1913

  • Kerr JFR, Gobe GC, Winterford CM, Harmon BV . 1995 Methods Cell Biol. 46: 1–22

  • Khaled AR, Kim K, Hofmeister R, Muegge K, Durum SK . 1999 Proc. Natl. Acad. Sci. USA 96: 14476–14481

  • Kim IK, Chung CW, Woo HN, Hong GS, Nagata S, Jung YK . 2000 Biochem. Biophys. Res. Commun. 277: 311–316

  • King MP, Attardi G . 1989 Science 246: 500–503

  • Kroemer G, Zamzami N, Susin SA . 1997 Immunol. Today 18: 44–51

  • Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X . 1997 Cell 91: 479–489

  • Liang BC, Ullyatt E . 1998 Cell Death Differ. 5: 694–701

  • Lincz LF, Yeh TX, Spencer A . 2001 Leukemia 15: 1650–1657

  • Liu X, Kim CN, Yang J, Jemmerson R, Wang X . 1996 Cell 86: 147–157

  • Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A, Kroemer G . 1996 Cancer Res. 56: 2033–2038

  • Pan G, Ni J, Yu G, Wei Y, Dixit VM . 1998 FEBS Letts 424: 41–45

  • Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM . 1997 Science 276: 111–113

  • Park K-S, Nam K-J, Kim J-W, Lee Y-B, Han C-Y, Jeong J-K, Lee H-K, Pak YK . 2001 Am. J. Physiol. 280: E1007–E1014

  • Perez D, White E . 2000 Mol. Cell 6: 53–63

  • Polyak K, Li Y, Zhu H, Lengauer C, Willson JKV, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B . 1998 Nat. Genet. 20: 291–293

  • Rubin BY, Smith LJ, Hellermann GR, Lunn RM, Richardson NK, Anderson SL . 1988 Cancer Res. 48: 6006–6010

  • Sambrook J, Fritsch E, Maniatis T . 1989 Molecular cloning. a laboratory manual 2nd edn Cold Spring Harbor Laboratory Press: Cold Spring Harbor

    Google Scholar 

  • Schneider P, Thome M, Burns K, Bodmer J, Hofmann K, Kataoka T, Holler N, Tschopp J . 1997 Immunity 7: 831–836

  • Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G, Fiers W . 1993 EMBO J. 12: 3095–3104

  • Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A . 1997 Science 277: 818–821

  • Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y . 1996 Cancer Res. 56: 2161–2166

  • Skowronek P, Haferkamp O, Rodel G . 1992 Biochem. Biophys. Res. Commun. 187: 991–998

  • Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura H . 2001 J. Exp. Med. 193: 661–670

  • Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K . 2001 Nat. Med. 7: 94–100

  • Thomas WD, Hersey P . 1998 J. Immunol. 161: 2195–2200

  • Thomas WD, Zhang XD, Franco AV, Nguyen T, Hersey P . 2000 J. Immunol. 165: 5612–5620

  • Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM . 1996 Science 274: 787–789

  • Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT, Thompson CB . 1997 Cell 91: 627–637

  • Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JCL, Lynch D . 1999 Nat. Med. 5: 157–163

  • Wang J, Zheng L, Lobito A, Chan F, Dale J, Sneller M, Yao X, Puck JM, Straus SE, Lenardo MJ . 1999 Cell 98: 47–58

  • Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, Youle RJ . 1997 J. Cell Biol. 139: 1281–1292

  • Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dorken B, Ludwig WD, Karawajew L . 2001 Leukemia 15: 921–928

  • Yamada H, Tada-Oikawa S, Uchida A, Kawanishi S . 1999 Biochem. Biophys. Res. Commun. 265: 130–133

  • Yeh W, Pompa JL, McCurrach ME, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SE, Goeddel DV, Mak TW . 1998 Science 279: 1954–1957

Download references

Acknowledgements

The authors thank Drs K Suk, H-Y Park and P-G Suh for helpful discussion. This work was supported by the National Research Laboratory Grants from the Korea Institute of Science and Technology Evaluation and Planning (2000-N-NL-01-C-232), and Science Research Center Grants from Korea Science and Engineering Foundation. M-S Lee is an awardee of the Juvenile Diabetes Foundation International Research Grant (1-1999-760).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Myung-Shik Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, JY., Kim, YH., Chang, I. et al. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis. Oncogene 21, 3139–3148 (2002). https://doi.org/10.1038/sj.onc.1205406

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205406

Keywords

This article is cited by

Search

Quick links